Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (1616)	4/3/2001 4:52:45 PM
From: Jibacoa	Read Replies (2) of 2344

<<Mean Survival is less than 6 months for metastatic Breast Cancer? >> Ian, I am not sure what is the average survival. I suppose it depends of the stage at entry and also may be affected by other variables like what other therapy is been applied. If I remember correctly, in the phase II, the average survival of controls were 9 months and the group that received the vaccine was 27 months. Now they are using a vaccine which supposedly is 100 times more potent "antigenically". I think if the results show an statistically significant difference even if it is 1/2 as good as in Phase II, there should be no problems for them to apply to the FDA for an expedited approval. And if results look good, even if the FDA doesn't grant approval soon, since this is an international trial, Canada or Europe may give the green light before the FDA. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next